AKYA

Akoya Biosciences, Inc. [AKYA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AKYA Stock Summary

Top AKYA Correlated Resources

AKYA


Top 10 Correlated Stocks

AKYA


In the News

08:04 08 Dec 2022 AKYA

Akoya Biosciences, Inc. (AKYA) Q3 2022 Earnings Call Transcript

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Priyam Shah - Senior Director, Investor Relations Brian McKelligon - Chief Executive Officer Joseph Driscoll - Chief Financial Officer Conference Call Participants Mason Carrico - Stephens Mark Massaro - BTIG Neil Vibhakar - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2022 Earnings Conference Call.

06:56 08 Dec 2022 AKYA

Akoya Biosciences (AKYA) Reports Q3 Loss, Tops Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -17.50% and 5.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

08:05 08 Dec 2022 AKYA

Akoya to Participate at Three Upcoming Investor Conferences

MARLBOROUGH, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in three upcoming investor conferences.

08:05 08 Dec 2022 AKYA

Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022

MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

08:05 08 Dec 2022 AKYA

Akoya to Participate at Four Upcoming Investor Conferences

MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming investor conferences.

10:38 08 Dec 2022 AKYA

Title: Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q2 2022 Results - Earnings Call Transcript

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Priyam Shah - Head of IR Brian McKelligon - CEO Joseph Driscoll - CFO Conference Call Participants Neil Vibhakar - Morgan Stanley Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG David Westenberg - Piper Sandler Operator Thank you for standing by, and welcome to the Akoya Biosciences Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode.

07:34 08 Dec 2022 AKYA

Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -38.24% and 5.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

08:05 08 Dec 2022 AKYA

Akoya to Participate at Two Upcoming Investor Conferences

MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in two upcoming investor conferences.

08:05 08 Dec 2022 AKYA

Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022

MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2022 after the market close on Monday, August 8th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

07:42 08 Dec 2022 AKYA

Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q1 2022 Results - Earnings Call Transcript

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Priyam Shah - Head of IR Brian McKelligon - CEO Joe Driscoll - CFO Conference Call Participants Dave Westenberg - Piper Sandler Edmund Tu - Morgan Stanley Operator Welcome to the Akoya Biosciences First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded.

AKYA Financial details

Company Rating
Neutral
Market Cap
488.49M
Income
-69.44M
Revenue
43.25M
Book val./share
1.98
Cash/share
2.16
Dividend
-
Dividend %
-
Employees
319
Optionable
No
Shortable
Yes
Earnings
07 Nov 2022
P/E
-8.2
Forward P/E
-
PEG
-0.56
P/S
10.34
P/B
5.96
P/C
5.71
P/FCF
-8.95
Quick Ratio
2.85
Current Ratio
3.53
Debt / Equity
0.83
LT Debt / Equity
0.83
-
-
EPS (TTM)
-1.85
EPS next Y
-
EPS next Q
-
EPS this Y
97.97%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
5.35%
EPS Q/Q
-
-
-
-
-
SMA20
-7.69%
SMA50
9.09%
SMA100
-14.29%
Inst Own
38.24%
Inst Trans
3.59%
ROA
-39%
ROE
-71%
ROC
-0.45%
Gross Margin
-13%
Oper. Margin
-151%
Profit Margin
-161%
Payout
-
Shs Outstand
37.96M
Shs Float
12.9M
-
-
-
-
Target Price
17
52W Range
8.02-16.57
52W High
-22.88%
52W Low
+54.25%
RSI
42
Rel Volume
0.13
Avg Volume
150.52K
Volume
19.81K
Perf Week
-4.93%
Perf Month
-6.44%
Perf Quarter
32.83%
Perf Half Y
15.87%
-
-
-
-
Beta
-
-
-
Volatility
0.53%, 0.62%
Prev Close
4.58%
Price
12.34
Change
0.41%

AKYA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2021-12-31
Revenue per share
1.9
Net income per share
-1.48
Operating cash flow per share
0
Free cash flow per share
0
Cash per share
3.91
Book value per share
4.2
Tangible book value per share
2.83
Share holders equity per share
4.2
Interest debt per share
1.02
Market cap
302.17M
Enterprise value
221.57M
P/E ratio
-7.04
Price to sales ratio
5.5
POCF ratio
0
PFCF ratio
0
P/B Ratio
2.49
PTB ratio
2.49
EV to sales
4.03
Enterprise value over EBITDA
-5.34
EV to operating cash flow
0
EV to free cash flow
0
Earnings yield
-0.14
Free cash flow yield
0
Debt to equity
0.27
Debt to assets
0.36
Net debt to EBITDA
1.94
Current ratio
5.09
Interest coverage
12.62
Income quality
0
Dividend Yield
0
Payout ratio
-0.03
Sales general and administrative to revenue
0
Research and developement to revenue
0.29
Intangibles to total assets
0.21
Capex to operating cash flow
0
Capex to revenue
0
Capex to depreciation
0
Stock based compensation to revenue
0
Graham number
11.84
ROIC
-0.24
Return on tangible assets
-0.28
Graham Net
1.91
Working capital
113.13M
Tangible asset value
81.94M
Net current asset value
71.26M
Invested capital
0.27
Average receivables
7.96M
Average payables
7.25M
Average inventory
6.64M
Days sales outstanding
62.77
Days payables outstanding
83.19
Days of inventory on hand
79.48
Receivables turnover
5.82
Payables turnover
4.39
Inventory turnover
4.59
ROE
-0.35
Capex per share
0

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
0.36-0.280.450.480.5
Net income per share
-0.31-0.47-0.44-0.47-0.47
Operating cash flow per share
-0.360-0.48-0.36-0.32
Free cash flow per share
-0.410-0.51-0.4-0.42
Cash per share
3.233.042.512.332.16
Book value per share
3.73.262.842.421.98
Tangible book value per share
2.632.21.81.380.96
Share holders equity per share
3.73.262.842.421.98
Interest debt per share
0.910.731.191.511.76
Market cap
518.79M570.33M411.73M483.32M445.33M
Enterprise value
431.54M489.72M361.51M492.38M459.22M
P/E ratio
-11.16-8.07-6.28-6.91-6.23
Price to sales ratio
38.5-54.924.3727.0123.62
POCF ratio
-38.730-22.96-36.11-36.59
PFCF ratio
-33.970-21.59-32.33-27.9
P/B Ratio
3.784.73.865.325.93
PTB ratio
3.784.73.865.325.93
EV to sales
32.02-47.1421.427.5224.36
Enterprise value over EBITDA
-44.85-22.39-25.81-33.16-31.79
EV to operating cash flow
-32.220-20.16-36.78-37.73
EV to free cash flow
-28.260-18.96-32.94-28.77
Earnings yield
-0.02-0.03-0.04-0.04-0.04
Free cash flow yield
-0.030-0.05-0.03-0.04
Debt to equity
0.240.270.380.580.83
Debt to assets
0.30.360.430.510.57
Net debt to EBITDA
9.073.693.58-0.61-0.96
Current ratio
8.425.093.983.553.53
Interest coverage
-14.073.12-20.77-19.21-15.02
Income quality
1.1501.090.770.68
Dividend Yield
00000
Payout ratio
0-0.08000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.3-0.540.340.310.29
Intangibles to total assets
0.20.210.210.210.22
Capex to operating cash flow
0.1400.060.120.31
Capex to revenue
-0.140-0.07-0.09-0.2
Capex to depreciation
-1.510-0.7-0.93-1.95
Stock based compensation to revenue
0.0900.090.10.11
Graham number
5.15.95.295.034.58
ROIC
-0.06-0.1-0.1-0.11-0.12
Return on tangible assets
-0.07-0.12-0.11-0.12-0.13
Graham Net
1.951.480.730.23-0.17
Working capital
128.36M113.13M94.73M86.11M80.06M
Tangible asset value
97.76M81.94M67.33M51.79M36.38M
Net current asset value
87.64M71.26M45.89M26.48M10.38M
Invested capital
0.240.270.410.620.88
Average receivables
10.04M9.96M10.89M10.47M9.58M
Average payables
8.72M11.4M12.45M13.37M10.77M
Average inventory
9.66M11.12M12.3M13.22M13.14M
Days sales outstanding
64.15-81.8160.2752.6741.44
Days payables outstanding
72.9431.89152.49159.3492.57
Days of inventory on hand
109.1730.46150.57157.5147.98
Receivables turnover
1.4-1.11.491.712.17
Payables turnover
1.232.820.590.560.97
Inventory turnover
0.822.950.60.570.61
ROE
-0.08-0.15-0.15-0.19-0.24
Capex per share
-0.050-0.03-0.04-0.1

AKYA Frequently Asked Questions

What is Akoya Biosciences, Inc. stock symbol ?

Akoya Biosciences, Inc. is a US stock , located in Marlborough of Ma and trading under the symbol AKYA

Is Akoya Biosciences, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $17. The lowest prediction is $17 and the highest is $17

What is AKYA stock prediction ?

What is Akoya Biosciences, Inc. stock quote today ?

Akoya Biosciences, Inc. stock price is $12.34 today.

Is Akoya Biosciences, Inc. stock public?

Yes, Akoya Biosciences, Inc. is a publicly traded company.

Something similar

Top Correlated Stocks
Similar Market Cap